KEGG   DISEASE: Endometrial cancer
Entry
H00026                      Disease                                
Name
Endometrial cancer
Description
Endometrial cancer (EC) is the most common gynaecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy, p53 mutations, and her2/neu amplification.
Category
Cancer
Brite
Human diseases in ICD-11 classification [BR:br08403]
 02 Neoplasms
  Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues
   Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
    Malignant neoplasms of female genital organs
     2C76  Malignant neoplasms of corpus uteri
      H00026  Endometrial cancer
Pathway-based classification of diseases [BR:br08402]
 Signal transduction
  nt06526  MAPK signaling
   H00026  Endometrial cancer
  nt06505  WNT signaling
   H00026  Endometrial cancer
Cancer-associated carbohydrates [br08441.html]
 H00026
Disease
pathway
hsa05213  Endometrial cancer
Network
nt06271 Endometrial cancer
nt06505 WNT signaling
Gene
ERBB2 (amplification) [HSA:2064] [KO:K05083]
PTEN (mutation, deletions, methylation) [HSA:5728] [KO:K01110]
MLH1 (mutation, methylation) [HSA:4292] [KO:K08734]
KRAS [HSA:3845] [KO:K07827]
CTNNB1 [HSA:1499] [KO:K02105]
TP53 [HSA:7157] [KO:K04451]
MSH3 [HSA:4437] [KO:K08736]
CDH1 [HSA:999] [KO:K05689]
Drug
Medroxyprogesterone acetate [DR:D00951]
Lenvatinib mesylate [DR:D09920]
Pembrolizumab [DR:D10574] (MSI-H or dMMR)
Dostarlimab [DR:D11366]
Other DBs
ICD-11: 2C76
ICD-10: C54
MeSH: D016889
OMIM: 608089
Reference
  Authors
Hecht JL, Mutter GL.
  Title
Molecular and pathologic aspects of endometrial carcinogenesis.
  Journal
J Clin Oncol 24:4783-91 (2006)
DOI:10.1200/JCO.2006.06.7173
Reference
  Authors
Ryan AJ, Susil B, Jobling TW, Oehler MK.
  Title
Endometrial cancer.
  Journal
Cell Tissue Res 322:53-61 (2005)
DOI:10.1007/s00441-005-1109-5
Reference
  Authors
Salvesen HB, Akslen LA.
  Title
Molecular pathogenesis and prognostic factors in endometrial carcinoma.
  Journal
APMIS 110:673-89 (2002)
DOI:10.1034/j.1600-0463.2002.1101001.x
Reference
  Authors
Shiozawa T, Konishi I.
  Title
Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.
  Journal
Int J Clin Oncol 11:13-21 (2006)
DOI:10.1007/s10147-005-0546-1
Reference
PMID:8782829 (MSH3)
  Authors
Risinger JI, Umar A, Boyd J, Berchuck A, Kunkel TA, Barrett JC
  Title
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair.
  Journal
Nat Genet 14:102-5 (1996)
DOI:10.1038/ng0996-102
Reference
PMID:8075649 (CDH1)
  Authors
Risinger JI, Berchuck A, Kohler MF, Boyd J
  Title
Mutations of the E-cadherin gene in human gynecologic cancers.
  Journal
Nat Genet 7:98-102 (1994)
DOI:10.1038/ng0594-98

» Japanese version

DBGET integrated database retrieval system